Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX Stok Raporu

Piyasa değeri: US$137.5m

Black Diamond Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Black Diamond Therapeutics CEO'su Mark Velleca, Sep2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 3.39M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.3% maaş ve 94.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.082% ine doğrudan sahiptir ve bu hisseler $ 113.05K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 4.4 yıldır.

Anahtar bilgiler

Mark Velleca

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi5.3%
CEO görev süresi1.2yrs
CEO sahipliği0.08%
Yönetim ortalama görev süresi2.6yrs
Yönetim Kurulu ortalama görev süresi4.4yrs

Son yönetim güncellemeleri

Recent updates

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Oct 30
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 08

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05
What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01
Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond nominates development candidate for glioblastoma program

Nov 20

Black Diamond Therapeutics EPS beats by $0.02

Nov 10

Black Diamond Therapeutics: One To Watch In Precision Oncology Space

Oct 23

CEO Tazminat Analizi

Mark Velleca'un ücretlendirmesi Black Diamond Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$73m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$3mUS$180k

-US$82m

Sep 30 2023n/an/a

-US$84m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$87m

Dec 31 2022US$65kn/a

-US$91m

Sep 30 2022n/an/a

-US$96m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$204kn/a

-US$126m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 3.39M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).

Tazminat ve Kazançlar: Mark şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Mark Velleca (60 yo)

1.2yrs

Görev süresi

US$3,387,383

Tazminat

Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mark Velleca
CEO, President & Chairman1.2yrsUS$3.39m0.082%
$ 113.1k
David M. Epstein
Co-Founder & Directorno dataUS$2.02m1.61%
$ 2.2m
Fang Ni
Advisorless than a yearUS$1.49m0.23%
$ 311.8k
Sergey Yurasov
Chief Medical Officer2.4yrsUS$1.23m0%
$ 0
Elizabeth Buck
Co-Founder & Chief Scientific Officer3.3yrsUS$347.30kVeri yok
Erika Jones
Principal Financial Officer3.8yrsVeri yokVeri yok
Brent Hatzis-Schoch
COO & General Counsel5.5yrsUS$911.23k0.015%
$ 20.4k
Elizabeth Montgomery
Chief People Officer2.8yrsVeri yokVeri yok
Melanie Morrison
Chief Development Officer2yrsVeri yokVeri yok

2.6yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: BDTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mark Velleca
CEO, President & Chairman3.3yrsUS$3.39m0.082%
$ 113.1k
David M. Epstein
Co-Founder & Director8.2yrsUS$2.02m1.61%
$ 2.2m
Ali Behbahani
Independent Director5.9yrsUS$68.14k0.10%
$ 139.9k
Garry Menzel
Independent Director7.7yrsUS$75.35k0.14%
$ 186.3k
Kapil Dhingra
Independent Director3.8yrsUS$109.35k0.018%
$ 24.3k
Samarth Kulkarni
Lead Independent Director5yrsUS$59.35k0%
$ 0
Prakash Raman
Independent Directorless than a yearVeri yok0.0088%
$ 12.1k
Shannon Campbell
Independent Directorless than a yearVeri yok0.0077%
$ 10.6k

4.4yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BDTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).